NEW YORK (GenomeWeb) – Foundation Medicine today said that it has signed a licensing deal with WuXi PharmaTech, enabling that firm to offer Foundation Medicine's genomic profiling technology to companies conducting clinical trials in China.
Under the terms of the agreement, WuXi will perform the laboratory component of Foundation Medicine's FoundationOne test at the WuXi Genome Center in Shanghai, which the firm's noted is the first and only CLIA-certified lab in China. Financial and other tersm of the deal weren't disclosed.
FoundationOne interrogates the entire coding region in 315 genes and select introns in 28 genes that are commonly altered in solid tumors.
"The development and use of targeted therapies and comprehensive diagnostic tests in oncology are expected to grow significantly in China," Foundation Medicine President and CEO Michael Pellini said in a statement. "WuXi's leadership position in China makes WuXi an ideal partner as Foundation Medicine expands its global reach to support targeted drug development and clinical entry into this rapidly growing market."